Navigation Links
Spiriva has Closed the Gap in Patient Share Between Itself and Advair for the Treatment of COPD
Date:12/22/2009

WALTHAM, Mass., Dec. 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.

"Surveyed U.S. primary care physicians (PCPs) expect to use more of Spiriva over the next two years while their enthusiasm around Advair is waning compared to last year's analysis," stated Decision Resources Analyst Amanda Puffer. "Almost 60 percent of PCPs say they will increase their use of Spiriva over the next two years and only eight percent think their use of the drug will decline. This is important to note because last year's analysis indicated that a lot of Advair's use was driven by PCPs."

The new report entitled Treatment Algorithms in Chronic Obstructive Pulmonary Disease also finds that the declining use of Advair may be due in part to increased use of AstraZeneca's Symbicort, which was approved for COPD in February of 2009. Patient-level claims data indicates that even prior to its approval, Symbicort was gaining ground in this market and compared to last year's analysis, Symbicort's patient share in the second line increased by 2.8 percentage points.

By combining patient-level claims data with physician survey data, this report can be used to build patient-flow models and analyze the assumptions driving these models. Patient-level claims data show that more patients (11%) use Symbicort directly after having used Advair while a significantly lower number (2%) of Advair users arrive at the drug after having used Symbicort. Compared to last year's analysis, 15.3 percent of second-line and later Symbicort patients moved to the agent after having tried Advair. This indicates that Symbicort is being used more frequently as a first-line maintenance therapy than one year ago.

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from IMS Lifelink: Health Plans Claims database to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.


    For more information, contact:
    Gisselle Morales                             Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    gmorales@dresources.com                      emarshall@dresources.com


SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Quest Diagnostics Finalizes Previously Announced Settlement With Government Related to Test Kit Subsidiary Closed in 2006
2. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
3. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
4. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
5. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
6. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
7. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
8. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
9. FDA researchers identify new MRI safety risk for patients with pacemakers
10. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
11. Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... 2, 2016 Q BioMed Inc. ... partner Mannin Research Inc. will be attending the Association ... place from May 1-5, 2016 in Seattle ... with its vendors and research partners. The meeting provides ... and other collaborative opportunities for the MAN-01 program for ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... personalized pain medicine, is excited to announce the launch of the Proove ... health studies, volunteerism, and education to promote the use of personalized medicine for ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Intelligent Implant ... by the FDA via 510(k) for sale in the United States. These components ... posterior thoraco-lumbar fusions. With one-level sales beginning in October of 2015, the company ...
(Date:4/28/2016)... ... 2016 , ... Next week on May 5 at 2:55 ... for tissue stem cell counting and expansion to gene-editing scientists and other attendees ... Genome Engineering in Burlington, Massachusetts. , The attention of most gene-editing scientists appears ...
Breaking Biology Technology:
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/17/2016)... 17, 2016 ABI Research, the leader ... global biometrics market will reach more than $30 ... from 2015. Consumer electronics, particularly smartphones, continue to ... anticipated to reach two billion shipments by 2021 ... Pavlakis , Research Analyst at ABI Research. "Surveillance ...
(Date:3/11/2016)... Germany , March 11, 2016 http://www.apimages.com ... - Cross reference: Picture is available at AP Images ( http://www.apimages.com ... from DERMALOG will be used to produce the new refugee identity ... other biometric innovations, at CeBIT in Hanover ... scanner from DERMALOG will be used to produce the new refugee ...
Breaking Biology News(10 mins):